PURAC Biochem BV

PURAC Biochem BV has been granted 121 US utility patents between 2015 and 2025, placing PURAC Biochem BV at rank #3,123 across all assignees tracked by PlainPatent. This portfolio spans 57 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.7 claims per patent with primary concentration in C12P (FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE). As a Foreign Corporation, PURAC Biochem BV is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 55.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 60 grants, compared with 61 in the 2015–2019 window — a -2% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. PURAC Biochem BV's 16.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 57 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark PURAC Biochem BV against peers pursuing similar technology classes.